. Author manuscript; available in PMC: 2021 Apr 12.

Published in final edited form as: J Thromb Haemost. 2018 Jun 21;16(7):1369–1382. doi: 10.1111/jth.14148

Table 2.

Overview of the study designs for the mouse tail vein transection bleeding studies

Figure	Group	Strain	Type of HA	Mice (n)	Treatment (dose, mg kg⁻¹)	Design
3A-D	1	FVIII^−/−	Congenital	16	Vehicle	S and B
	2	FVIII^−/−	Congenital	15	TXA (500)	S and B
	3	FVIII^−/−	Congenital	15	rFVIIa (0.4 ~ ED₅₀)	S and B
	4	FVIII^−/−	Congenital	15	rFVIIa (0.4 ~ ED₅₀) + TXA (500)	S and B
	5	C57Bl/6	-	8	Vehicle	S
3E-H	1	FVIII^−/−	Congenital	12	Vehicle	S and B
	2	FVIII^−/−	Congenital	12	TXA (500)	S and B
	3	FVIII^−/−	Congenital	12	rFVIII (1 U kg⁻¹ ~ ED₅₀)	S and B
	4	FVIII^−/−	Congenital	12	rFVIII (1 U kg⁻¹ ~ ED₅₀) + TXA (500)	S and B
	5	C57Bl/6	-	8	Vehicle	S
4A-D	1	C57Bl/6	Induced	12	TXA (350)	S
	2	C57Bl/6	Induced	12	Vehicle	S and B
	3	C57Bl/6	Induced	12	rFVIIa (0.4)	S and B
	4	C57Bl/6	Induced	12	rFVIIa (0.4) + TXA (350)	S and B
	5	C57Bl/6	Induced	12	rFVIIa (0.7 ~ ED₅₀)	S & B
	6	C57Bl/6	Induced	12	rFVIIa (0.7~ED₅₀) + TXA (350)	S and B
	7	C57Bl/6	-	8	Vehicle	S
5A-D	1	t-PA WT	Induced	8	Vehicle	S
		t-PA^−/−	Induced	8
	2	t-PA WT	Induced	10	rFVIIa (0.7 ~ ED₅₀)	S
		t-PA^−/−	Induced	8
	3	t-PA WT	Induced	8	rFVIIa (1.5)	S
		t-PA^−/−	Induced	8
	4	t-PA WT	Induced	8	rFVIIa (2.7)	S
		t-PA^−/−	Induced	8
	5	t-PA WT	-	8	Vehicle	S
		t-PA^−/−	-	8
5E-D	1	Plg WT	Induced	8	Vehicle	S
		Plg^−/−	Induced	11
	2	Plg WT	Induced	10	rFVIIa (0.7 ~ ED₅₀)	S
		Plg^−/−	Induced	7
	3	Plg WT	Induced	7	rFVIIa (1.5)	S
		Plg^−/−	Induced	8
	4	Plg WT	Induced	8	rFVIIa (2.7)	S
		Plg^−/−	Induced	9
	5	Plg WT	-	7	Vehicle	S
		Plg^−/−	-	5

B, blinded; ED₅₀, median effective dose; FVIII, coagulation factor VIII; HA, hemophilia A; Plg, plasminogen; rFVIIa, activated recombinant factor VII; rFVIII, recombinant factor VIII; S, stratified; t-PA, tissue-type plasminogen activator; TXA, tranexamic acid; WT, wild type. Data from the study are shown in Figs 3–5.